Pyrimidines

On March 31, 2020, Pfeiffer, Per; Yilmaz, Mette; Moller, Soren; Zitnjak, Daniela; Krogh, Merete; Petersen, Lone Noergaard; Poulsen, Laurids Oestergaard; Winther, Stine Braendegaard; Thomsen, Karina Gravgaard; Qvortrup, Camilla published an article.Recommanded Product: 65-71-4 The title of the article was TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. And the article contained the following:

TAS-102 (trifluridine-tipiracil) has shown a significant overall survival benefit compared with placebo in patients with chemorefractory metastatic colorectal cancer. Inspired by the encouraging results of a small phase 1-2 study, C-TASK FORCE, which evaluated the combination of TAS-102 plus bevacizumab in patients with chemorefractory metastatic colorectal cancer, we aimed to compare the efficacy of TAS-102 plus bevacizumab vs. TAS-102 monotherapy in patients receiving refractory therapy for metastatic colorectal cancer . This investigator-initiated, open-label, randomized, phase 2 study enrolled patients (aged ≥18 years) with metastatic colorectal from four cancer centers in Denmark. The main inclusion criteria were histopathol. confirmed metastatic colorectal cancer refractory or intolerant to a fluoropyrimidine, irinotecan, oxaliplatin, and cetuximab or panitumumab (only for RAS wild-type), and WHO performance status of 0 or 1. Previous therapy with bevacizumab, aflibercept, ramucirumab, or regorafenib was allowed but not mandatory. Participants were enrolled and randomly assigned (1:1) in block sizes of two, four, or six by a web-based tool to receive oral TAS-102 (35 mg/m2 twice daily on days 1-5 and 8-12 every 28 days) alone or combined with i.v. bevacizumab (5 mg/kg on days 1 and 15) until progression, unacceptable toxicity, or patient decision to withdraw. Treatment assignment was not masked, and randomization was stratified by institution and RAS mutation status. The primary endpoint was investigator-evaluated progression-free survival. All analyses were based on intention to treat. This trial is registered with EudraCT, 2016-005241-23. From Aug 24, 2017, to Oct 31, 2018, 93 patients were enrolled and randomly assigned to TAS-102 (n = 47) or TAS-102 plus bevacizumab (n = 46). The clin. cut-off date was Feb 15, 2019, after a median follow-up of 10.0 mo (IQR 6.8-14.0). Median progression-free survival was 2.6 mo (95% CI 1.6-3.5) in the TAS-102 group vs. 4.6 mo (3.5-6.5) in the TAS-102 plus bevacizumab group (hazard ratio 0.45 [95% CI 0.29-0.72]; p = 0.0015). The most frequent grade 3 or worse adverse event was neutropenia (18 [38%] of 47 in the TAS-102 monotherapy group vs 31 [67%] of 46 in the TAS-102 plus bevacizumab group). Serious adverse events were observed in 21 (45%) patients in the TAS-102 group and 19 (41%) in the TAS-102 plus bevacizumab group. No deaths were deemed treatment related. In patients with chemorefractory metastatic colorectal cancer, TAS-102 plus bevacizumab, as compared with TAS-102 monotherapy, was associated with a significant and clin. relevant improvement in progression-free survival with tolerable toxicity. The combination of TAS-102 plus bevacizumab could be a new treatment option for patients with refractory metastatic colorectal cancer and could be a practice-changing development.Servier. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 65-71-4

The Article related to tas bevacizumab fluoropyrimidine anticancer agent colorectal cancer metastasis, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Ogata, Misato; Kotaka, Masahito; Ogata, Takatsugu; Hatachi, Yukimasa; Yasui, Hisateru; Kato, Takeshi; Tsuji, Akihito; Satake, Hironaga published an article in 2020, the title of the article was Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.COA of Formula: C5H6N2O2 And the article contains the following content:

Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) showed survival benefits in metastatic colorectal cancer patients previously treated with standard chemotherapies; therefore, we compared the efficacy and safety of these two treatments. Patients with metastatic colorectal cancer treated with REG or FTD/TPI as a salvage-line therapy from May 2014 to Dec. 2017 were included. We retrospectively analyzed long-term survival, safety, and clin. outcomes. Among 134 patients, 57 and 77 received REG and FTD/TPI, resp. The REG group received more prior systemic chemotherapies and significantly more frequent addnl. chemotherapies than the FTD/TPI group did. The median follow-up was 6.2 mo, whereas the median overall survival was 9.9 and 11.4 mo in the REG and FTD/TPI groups, resp. (hazard ratio = 0.954, p = 0.837). The median progression-free survival was 2.0 and 3.3 mo in the REG and FTD/TPI groups, resp. (hazard ratio = 0.52, p = 0.00047), indicating significant differences, whereas the objective response and disease control rates did not differ. The median overall survival of patients with addnl. subsequent chemotherapies after disease progression was longer than that of patients without addnl. chemotherapy. The most frequent grade ≥3 adverse events were hypertension and neutropenia in the REG and FTD/TPI groups, resp. Our study suggested that sequential use of both drugs may prolong survival. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).COA of Formula: C5H6N2O2

The Article related to metastatic colorectal cancer regorafenib trifluridine tipiracil chemotherapy japan, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.COA of Formula: C5H6N2O2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 31, 2021, Yoshida, Yoichiro; Yamada, Takeshi; Kamiyama, Hirohiko; Kosugi, Chihiro; Ishibashi, Keiichiro; Yoshida, Hiroshi; Ishida, Hideyuki; Yamaguchi, Satoru; Kuramochi, Hidekazu; Fukazawa, Atsuko; Sonoda, Hiromichi; Yoshimatsu, Kazuhiko; Matsuda, Akihisa; Hasegawa, Suguru; Sakamoto, Kazuhiro; Otsuka, Toshiaki; Koda, Keiji; TAS CC3 Study Group. published an article.Reference of 5-Methylpyrimidine-2,4(1H,3H)-dione The title of the article was Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. And the article contained the following:

Abstract: Our study exclusively examined patients receiving this combination as a third-line treatment to investigate the clin. impact beyond cytotoxic doublets. Methods: This investigator-initiated, open-label, single-arm, multi-centered phase II study was conducted in Japan. Eligible CRC patients were refractory or intolerant to fluoropyrimidine, irinotecan, and oxaliplatin in first- and second-line therapy. TAS-102 (35 mg/m2) was given orally twice daily on days 1-5 and 8-12 in a 4-wk cycle, and bevacizumab (5 mg/kg) was administered by i.v. infusion every 2 wk. The primary endpoint was PFS and the secondary endpoints were time-to-treatment failure, response rate, overall survival (OS), and safety. Results: Between June 2016 and August 2017, 32 patients were enrolled. All patients previously received bevacizumab. The median PFS was 4.5 mo; the median overall survival was 9.3 mo. Partial response was observed in two patients. The most common adverse events above grade 3 were neutropenia followed by thrombocytopenia. There were no non-hematol. adverse events above grade 3 and no treatment-related deaths occurred. Conclusions: This study met its primary endpoint of PFS, which is comparable to the results of the C-TASK FORCE study. The TAS-102 and bevacizumab combination has the potential to be a therapeutic option for third-line treatment of metastatic CRC. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Reference of 5-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to metastatic colorectal cancer tas 102 bevacizumab japan, bevacizumab, chemotherapy, colorectal cancer, neutropenia, tas-102, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Reference of 5-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 31, 2020, Shibutani, Masatsune; Nagahara, Hisashi; Fukuoka, Tatsunari; Iseki, Yasuhito; Wang, En; Okazaki, Yuki; Kashiwagi, Shinichiro; Maeda, Kiyoshi; Hirakawa, Kosei; Ohira, Masaichi published an article.Computed Properties of 65-71-4 The title of the article was Combining bevacizumab with trifluridine/thymidine phosphorylase inhibitor improves the survival outcomes regardless of the usage history of bevacizumab in front-line treatment of patients with metastatic colorectal cancer. And the article contained the following:

The efficacy of trifluridine/thymidine phosphorylase inhibitor (FTD/TPI) plus bevacizumab as later-line treatment for metastatic colorectal cancer (mCRC) has been demonstrated. However, little is known about the impact of a usage history of bevacizumab in front-line treatment on the clin. benefit of combining bevacizumab with FTD/TPI. A total of 62 patients with mCRC treated with FTD/TPI±bevacizumab was enrolled and assessed for chemotherapeutic efficacy and adverse events. Regardless of the usage history of bevacizumab in front-line treatment, the FTD/TPI plus bevacizumab group had a significantly better progression-free survival rate than the FTD/TPI monotherapy group, and no significant differences in the safety profile were observed between the two groups. Combining bevacizumab with FTD/TPI improves the survival outcomes with manageable toxicity, regardless of the usage history of bevacizumab in front-line treatment, in patients with mCRC. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Computed Properties of 65-71-4

The Article related to metastatic colorectal cancer bevacizumab trifluridine thymidine phosphorylase inhibitor survival, ftd/tpi, tas-102, bevacizumab, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Computed Properties of 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 31, 2019, Luan, Yunpeng; Li, Yanmei; Yue, Xiaoguan; Cao, Yong; Xiang, Fei; Mao, Dechang; Xiong, Zhi published an article.Quality Control of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione The title of the article was Metabonomics of mice intestine in Codonopsis foetens induced apoptosis of intestine cancer cells. And the article contained the following:

Intestinal cancer is a disease with high morbidity and high mortality in China. Previous studies have shown that Codonopsis foetens can inhibit cellular autophagy and promote the apoptosis of intestine cancer cells. Based on metabolomics method coupled with liquid chromatog.-mass spectrometry (LC-MS) technol., we aimed to analyze intestinal small mol. metabolites in the intestinal cancer model group and the Codonopsis foetens treated group. Principal component anal. (PCA) and Partial Least Squares (PLS-DA) were used to identify the pattern of the data. And the metabolic characteristics of the cancer model group were explored based on the metabolic differences between the groups. Multivariate statistical anal. revealed that metabolites presented with differences included: Acetamide, Phosphoric acid, Hydrogen sulfite, Pyruvic acid, Cytosine, 2-Hydroxypyridine, Phosphoric acid, Uracil, Gamma-Aminobutyric acid, Glycerol alpha-monochlorohydrin, Thiosulfic acid, L-Valine, Cysteamine, Taurine, Creatine, Homocysteine, Hypoxanthine, Se-Methylselenocysteine, 5-Hydroxymethyluracil, Oxoglutaric acid, LysoPC(20:0), LysoPC(22:4(7Z,10Z,13Z,16Z)), LysoPC(18:2(9Z,12Z)), LysoPC(16:1(9Z)), LysoPE(0:0/16:0), LysoPE(0:0/18:2(9Z,12Z)), LysoPE(18:0/0:0), LysoPE(20:1(11Z)/0:0), etc. Combined with metabolic pathway anal., pathways presented with differences included: Citrate cycle (TCA cycle), ABC transporters, 2-Oxocarboxylic acid metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis, Biosynthesis of amino acids, Protein digestion and absorption, Aminoacyl-tRNA biosynthesis, C5-Branched dibasic acid metabolism, GABAergic synapse, Proximal tubule bicarbonate reclamation, Mineral absorption, Phenylalanine metabolism The results showed that the proliferation of intestinal cancer cells caused cell metabolism disorders, manifesting as changes in metabolic pathways and resulting in changes in metabolites. The experimental process involved the reaction of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione(cas: 4433-40-3).Quality Control of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione

The Article related to codonopsis metabonomic apoptosis intestine cancer cell, codonopsis foetens, intestinal cancer, metabolic pathway, metabolites, metabonomics, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Quality Control of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 31, 2020, Tabernero, Josep; Alsina, Maria; Shitara, Kohei; Doi, Toshihiko; Dvorkin, Mikhail; Mansoor, Wasat; Arkenau, Hendrik-Tobias; Prokharau, Aliaksandr; Ghidini, Michele; Faustino, Catia; Gorbunova, Vera; Zhavrid, Edvard; Nishikawa, Kazuhiro; Ando, Takayuki; Yalcin, Suayib; Van Cutsem, Eric; Sabater, Javier; Skanji, Donia; Leger, Catherine; Amellal, Nadia; Ilson, David H. published an article.Electric Literature of 65-71-4 The title of the article was Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. And the article contained the following:

Abstract: Background: In TAGS, an international, double-blind, phase 3 trial, trifluridine/tipiracil significantly improved overall survival and progression-free survival compared with placebo in heavily pretreated metastatic gastric cancer patients. This paper reports pre-specified quality of life (QoL) outcomes for TAGS. Methods: Patients were randomized 2:1 to trifluridine/tipiracil (35 mg/m2 twice daily on days 1-5 and 8-12 of each 28-day cycle) plus best supportive care (BSC) or placebo plus BSC. QoL was evaluated at baseline and at each treatment cycle, using the EORTC QLQ-C30 and EORTC QLQ-STO22 questionnaires; results were considered valid for anal. only if ≥ 10% of patients completed the questionnaires. Key QoL outcomes were mean changes from baseline and time to deterioration in QoL. A post hoc anal. assessed the association between QoL and time to deterioration of Eastern Cooperative Oncol. Group performance score (ECOG PS) to ≥ 2. Results: Of 507 randomized patients, 496 had baseline QoL data available. The anal. cut-off was 6 cycles for trifluridine/tipiracil and 3 cycles for placebo. In both treatment groups, there were no clin. significant deteriorations in the mean QLQ-C30 Global Health Status (GHS) score, or in most subscale scores. In a sensitivity anal. including death and disease progression as events, there was a trend towards trifluridine/tipiracil reducing the risk of deterioration of QoL scores compared with placebo. Deterioration in the GHS score was associated with deterioration in ECOG PS. Conclusion: QoL was maintained in TAGS, and there was a trend towards trifluridine/tipiracil reducing the risk of QoL deterioration compared with placebo. Trial registration ClinicalTrials.gov number: NCT02500043. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Electric Literature of 65-71-4

The Article related to trifluridine tipiracil anticancer agent gastric cancer metastasis, gastric cancer, health-related quality of life, phase 3, trifluridine/tipiracil, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Electric Literature of 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On April 30, 2020, Moriwaki, Toshikazu; Fukuoka, Shota; Masuishi, Toshiki; Takashima, Atsuo; Kumekawa, Yosuke; Kajiwara, Takeshi; Yamazaki, Kentaro; Esaki, Taito; Makiyama, Akitaka; Denda, Tadamichi; Hatachi, Yukimasa; Suto, Takeshi; Sugimoto, Naotoshi; Enomoto, Masanobu; Ishikawa, Toshiaki; Kashiwada, Tomomi; Oki, Eiji; Komatsu, Yoshito; Tsuji, Akihito; Tsuchihashi, Kenji; Sakai, Daisuke; Ueno, Hideki; Tamura, Takao; Yamashita, Kimihiro; Shimada, Yasuhiro published an article.Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione The title of the article was Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. And the article contained the following:

This study aimed to develop a prognostic scoring system for evaluating the overall survival (OS) benefit. Methods: Patients included in the REGOTAS study, which comprised 489 patients (regorafenib group: 199; FTD/TPI group: 290 patients), were evaluated. OS was analyzed using multivariate Cox proportional model. The prognostic score was calculated using the worst four individual factors weighted by hazard ratio, and the total scores were categorized as low-, moderate-, and high-OS benefit. Results: The worst four factors in the regorafenib group were AST > 40 IU/dL (point, + 3), CRP ≥ 1.0 mg/dL (+ 2), number of metastatic organ site ≥ 3 (+ 2), and duration from initiation of 1st-line chemotherapy < 18 mo (+ 2), while they were AST (+ 2), CRP (+ 2), CA19-9 > 37.0 U/mL (+ 2), and ECOG PS ≥ 1 (+ 2) in the FTD/TPI group. These corresponded to a total prognostic score of > 5, 2-4, and 0 points in the regorafenib group and 8, 2-6, and 0 points in the FTD/TPI group. The median OS in the low, moderate, and high OS benefit group was 3.3 (95% CI 3.0-3.7), 8.1 (95% CI 6.4-9.7), and 12.6 mo (95% CI 10.6-14.6) in the regorafenib group and 2.8 (95% CI 2.0-3.5), 7.5 (95% CI 6.6-8.3), and 15.4 mo (95% CI 9.7-21.2) in the FTD/TPI group. Conclusion: These prognostic scores are useful for identifying patients with mCRC who will obtain survival benefits from these drugs. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to colorectal cancer prognosis regorafenib trifluridine tipiracil, colorectal cancer, prognostic factor, regorafenib, tas-102, trifluridine/tipiracil, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Fujii, Hironori; Matsuhashi, Nobuhisa; Kitahora, Mika; Takahashi, Takao; Hirose, Chiemi; Iihara, Hirotoshi; Yamada, Yunami; Watanabe, Daichi; Ishihara, Takuma; Suzuki, Akio; Yoshida, Kazuhiro published an article in 2020, the title of the article was Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.Application In Synthesis of 5-Methylpyrimidine-2,4(1H,3H)-dione And the article contains the following content:

TAS-102 is effective for treating patients with metastatic colorectal cancer (mCRC). This study determined whether combining bevacizumab (Bmab) with TAS-102 improves clin. outcomes in refractory mCRC. We retrospectively analyzed data from Japanese patients with refractory mCRC who received TAS-102 (35 mg/m2, twice a day) with (T-B group) or without Bmab (TAS-102 monotherapy; T group) between July 2014 and Dec. 2018. The primary endpoint was median overall survival (OS), and secondary endpoints were median time to treatment failure, overall response rate, and the incidence of adverse events. Clin. outcomes were compared using propensity score matched anal. Data from 57 patients were analyzed (T-B group: 21 patients, T group: 36 patients). Median OS was significantly longer in the T-B group than the T group (14.4 mo vs. 4.5 mo, p < .001). Cox proportional hazard anal. showed that combination therapy with Bmab was significantly correlated with OS. Propensity score matched anal. confirmed that the median OS was significantly longer in the T-B group than the T group (14.4 mo vs. 6.1 mo, p = .006) and that there was a significant correlation between Bmab and OS. The incidence of hypertension (grade ≥2) as an adverse event was significantly higher in the T-B group than the T group (23.8% vs. 0.0%, p = .005), whereas other adverse events were comparable between the two groups. Treatment with Bmab in combination with TAS-102 is significantly associated with improved clin. outcomes in patients with mCRC refractory to standard therapies. Combining bevacizumab (Bmab) with TAS-102 significantly improved overall survival and several prognostic indicators in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies, with manageable toxicities. Treatment with Bmab in combination with TAS-102 is significantly associated with improved clin. outcomes in patients with mCRC. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Application In Synthesis of 5-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to bevacizumab tas102 anticancer agent metastatic colorectal cancer, bevacizumab, colorectal neoplasms, drug-related adverse reactions, survival, trifluridine, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Application In Synthesis of 5-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 31, 2020, Yoshino, T.; Cleary, J. M.; Van Cutsem, E.; Mayer, R. J.; Ohtsu, A.; Shinozaki, E.; Falcone, A.; Yamazaki, K.; Nishina, T.; Garcia-Carbonero, R.; Komatsu, Y.; Baba, H.; Argiles, G.; Tsuji, A.; Sobrero, A.; Yamaguchi, K.; Peeters, M.; Muro, K.; Zaniboni, A.; Sugimoto, N.; Shimada, Y.; Tsuji, Y.; Hochster, H. S.; Moriwaki, T.; Tran, B.; Esaki, T.; Hamada, C.; Tanase, T.; Benedetti, F.; Makris, L.; Yamashita, F.; Lenz, H.-J. published an article.Recommanded Product: 65-71-4 The title of the article was Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. And the article contained the following:

The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) vs. placebo in patients with refractory metastatic colorectal cancer. This post hoc anal. investigated pharmacokinetic data of FTD/TPI exposure and pharmacodynamic markers, such as chemotherapy-induced neutropenia (CIN) and clin. outcomes. A total of 210 patients from RECOURSE were enrolled in this substudy. A limited sampling approach was used, with three pharmacokinetic samples drawn on day 12 of cycle 1. Patients were categorized as being above or below the median area under the plasma concentration-time curve (AUC) for FTD and TPI. We conducted a post hoc anal. using the entire RECOURSE population to determine the correlations between CIN and clin. outcome. We then carried out a similar anal. on the J003 trial to validate the results. In the RECOURSE subset, patients in the high FTD AUC group had a significantly increased CIN risk. Analyses of the entire population demonstrated that FTD/TPI-treated patients with CIN of any grade in cycles 1 and 2 had significantly longer median overall survival (OS) and progression-free survival (PFS) than patients who did not develop CIN and patients in the placebo group. Patients who required an FTD/TPI treatment delay had increased OS and PFS vs. those in the placebo group and those who did not develop CIN. Similar results were obtained in the J003 cohort. In RECOURSE, patients with higher FTD drug exposure had an increased CIN risk. FTD/TPI-treated patients who developed CIN had improved OS and PFS vs. those in the placebo group and those who did not develop CIN. Similar findings were reported in the J003 cohort, thus validating the RECOURSE results. The occurrence of CIN may be a useful predictor of treatment outcomes for FTD/TPI-treated patients.NCT01607957 (RECOURSE).JapicCTI-090880 (J003). The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 65-71-4

The Article related to metastatic colorectal cancer neutropenia survival trifluridine tipiracil, ftd/tpi, j003, recourse, chemotherapy-induced neutropenia, metastatic colorectal cancer, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Oki, Eiji; Makiyama, Akitaka; Miyamoto, Yuji; Kotaka, Masahiko; Kawanaka, Hirofumi; Miwa, Keisuke; Kabashima, Akira; Noguchi, Tomohiro; Yuge, Kotaro; Kashiwada, Tomomi; Ando, Koji; Shimokawa, Mototsugu; Saeki, Hiroshi; Akagi, Yoshito; Baba, Hideo; Maehara, Yoshihiko; Mori, Masaki published an article in 2021, the title of the article was Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione And the article contains the following content:

A previous Phase I/II study demonstrated that TAS-102 (trifluridine/tipiracil) plus bevacizumab has encouraging efficacy and controllable safety for patients with previously treated metastatic colorectal cancer. Therefore, we designed for assessing efficacy and safety of FTD/TPI plus Bev in elderly patients with previously untreated metastatic colorectal cancer. Treatment consisted of FTD/TPI plus Bev given every 4 wk. Primary endpoint was progression-free survival, assuming null hypothesis of PFS of 5 mo. Secondary endpoints were the overall survival, overall response rate, and adverse events. Between 5 Jan. 2017 and 13 March 2018, 39 patients were enrolled from 18 institutions. Median patient age was 76.0 years (range, 70-88); the ECOG-PS was 0 in 24 patients and 1 in 15 patients. Median PFS was 9.4 mo as a primary endpoint, and the median OS was 22.4 mo. The ORR was 40.5% and the disease control rate was 86.5%. Grade 3-4 AEs included neutropenia, leukopenia, anorexia, febrile neutropenia, and fatigue. FTD/TPI plus Bev is effective and well-tolerated regimen for elderly patients with previously untreated metastatic colorectal cancer. Capecitabine/bevacizumab can be selected as subsequent maintenance therapy without irinotecan and oxaliplatin because FTD/TPI has no cross-resistance with 5-fluorouracil. Clin. trial registration, UMIN clin. trials registry (UMIN000025241). The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to metastatic colorectal cancer trifluridine tipiracil bevacizumab phase ii, trifluridine, bevacizumab, colorectal cancer, elderly, thymidine phosphorylase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia